TY - JOUR
T1 - Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
AU - De Simone, Clara
AU - Amerio, Paolo
AU - Amoruso, Giuseppe
AU - Bardazzi, Federico
AU - Campanati, Anna
AU - Conti, Andrea
AU - Gisondi, Paolo
AU - Gualdi, Giulio
AU - Guarneri, Claudio
AU - Leoni, Luca
AU - Loconsole, Francesco
AU - Mazzotta, Annamaria
AU - Musumeci, Maria Letizia
AU - Piaserico, Stefano
AU - Potenza, Concetta
AU - Prestinari, Francesca
PY - 2013
Y1 - 2013
N2 - Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity.
AB - Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity.
KW - immunogenecity
KW - immunogenecity
UR - http://hdl.handle.net/10807/51735
U2 - 10.1517/14712598.2013.848194
DO - 10.1517/14712598.2013.848194
M3 - Article
SN - 1471-2598
VL - 13
SP - 1673
EP - 1682
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
ER -